Document Type : Original Article

Authors

Department of Pharmacy Practice, Palamuru University (Smt. Sarojini Ramulamma College of Pharmacy), Sheshadrinagar, Mahabubnagar, 509001, Telangana, India

Abstract

Hypertensive disorders during pregnancy are a major public health concern in both developed and developing countries. Early detection and treatment of maternal health issues reduce the severity of these issues. This study set out to identify possible risk factors of these conditions and evaluate current methods of treatment. Throughout the research (6 months), 80 PIH women who met the inclusion criteria were studied in an observational study. Women in their twenties and thirties are more likely to have pregnancy-induced hypertension. Preeclampsia and gestational hypertension in pregnancy are the most common types. Hypertension issues are more common among pregnant women who are more likely to be obese, have had previous pregnancies, and reside in rural areas. Medication for the treatment of pregnancy-induced hypertension is prescribed and administered regarding drugs used for primary hypertension. Methyldopa and labetalol are examples of first-line treatments. Patients with PIH who are about to give birth are given hydralazine intravenously (IV) or nifedipine orally (P.O.) as a second-line treatment. When providing antihypertensive medicines or any other medications, the well-being of both maternal and fetal is taken into consideration. The risks to both mother and child may be reduced with prompt treatment with additional, safe medications.

Graphical Abstract

Pregnancy-induced hypertension: risk factors and current treatment strategies

Keywords

Main Subjects

Selected author of this article by journal

Dr.  Hafsa Ansari
Palamuru University
Google Scholar

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

 

Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.

 

Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Berhe AK, Kassa GM, Fekadu GA, Muche AA (2018) Prevalence of hypertensive disorders of pregnancy in Ethiopia: a systemic review and meta-analysis. BMC pregnancy and childbirth 18 (1): 1-11. doi: https://doi.org/10.1186/s12884-018-1667-7
  2. Davis EP, Narayan AJ (2020) Pregnancy as a period of risk, adaptation, and resilience for mothers and infants. Development and psychopathology 32 (5): 1625-1639. doi: https://doi.org/10.1017/S0954579420001121
  3. Oh C, Keats EC, Bhutta ZA (2020) Vitamin and mineral supplementation during pregnancy on maternal, birth, child health and development outcomes in low-and middle-income countries: a systematic review and meta-analysis. Nutrients 12 (2): 491. doi: https://doi.org/10.3390/nu12020491
  4. Muti M, Tshimanga M, Notion GT, Bangure D, Chonzi P (2015) Prevalence of pregnancy induced hypertension and pregnancy outcomes among women seeking maternity services in Harare, Zimbabwe. BMC cardiovascular disorders 15: 1-8. doi: https://doi.org/10.1186/s12872-015-0110-5
  5. Singh S, Doyle P, Campbell OM, Murthy G (2019) Management and referral for high-risk conditions and complications during the antenatal period: knowledge, practice and attitude survey of providers in rural public healthcare in two states of India. Reproductive health 16 (1): 1-14. doi: https://doi.org/10.1186/s12978-019-0765-y
  6. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR (2018) Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane database of systematic reviews 10 (10): CD001059. doi: https://doi.org/10.1002/14651858.CD001059.pub5
  7. Sibai BM (2003) Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics & Gynecology 102 (1): 181-192. doi: https://doi.org/10.1016/S0029-7844(03)00475-7
  8. Marek A, Stojko R, Drosdzol-Cop A (2021) Copeptin in patients with pregnancy-induced hypertension. International Journal of Environmental Research and Public Health 18 (12): 6470. doi: https://doi.org/10.3390/ijerph18126470
  9. Anonymous (2000) Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology 183 (1): s1-s22. doi: https://doi.org/10.1067/mob.2000.107928
  10. Traoré Y, Téguété I, Bocoum A, Traoré M, Dao S, Bomini MK, Mounkoro N, Dolo A (2018) Management and Prognosis of Early Postpartum Hemorrhage in African Low Setting Health. Open Journal of Obstetrics and Gynecology 8 (1): 1-9. doi: https://doi.org/10.4236/ojog.2018.81001
  11. Liu C-M, Cheng P-J, Chang S-D (2008) Maternal complications and perinatal outcomes associated with gestational hypertension and severe preeclampsia in Taiwanese women. Journal of the Formosan Medical Association 107 (2): 129-138. doi: https://doi.org/10.1016/S0929-6646(08)60126-6
  12. Srinivas S, Edlow A, Neff P, Sammel M, Andrela C, Elovitz M (2009) Rethinking IUGR in preeclampsia: dependent or independent of maternal hypertension? Journal of Perinatology 29 (10): 680-684. doi: https://doi.org/10.1038/jp.2009.83
  13. Chaemsaithong P, Sahota DS, Poon LC (2022) First trimester preeclampsia screening and prediction. American journal of obstetrics and gynecology 226 (2): S1071-S1097. e1072. doi: https://doi.org/10.1016/j.ajog.2020.07.020
  14. Anderson GD, Carr DB (2009) Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clinical pharmacokinetics 48: 159-168. doi: https://doi.org/10.2165/00003088-200948030-00002
  15. Magee LA (2001) Antihypertensives. Best practice & research Clinical obstetrics & gynaecology 15 (6): 827-845. doi: https://doi.org/10.1053/beog.2001.0232
  16. Podymow T, August P Antihypertensive drugs in pregnancy. In: Seminars in nephrology, 2011. vol 1. Elsevier, pp 70-85. doi: https://doi.org/10.1016/j.semnephrol.2010.10.007
  17. Mousa A, Mandili RL, Aljahdali M, Gari S, Khaimi S, Alahdal S, Derar RM, Marzook S, Mandili R, Derar II RM (2022) Maternal and Fetal Outcomes of Preeclampsia With and Without Severe Features in King Abdulaziz University Hospital, Jeddah, Saudi Arabia: A Retrospective Study. Cureus 14 (11). doi: 10.7759/cureus.31013
  18. Barr LC, Pudwell J, Smith GN (2021) Postpartum microvascular functional alterations following severe preeclampsia. American Journal of Physiology-Heart and Circulatory Physiology 320 (4): H1393-H1402. doi: https://doi.org/10.1152/ajpheart.00767.2020
  19. Kattah AG, Garovic VD (2013) The management of hypertension in pregnancy. Advances in chronic kidney disease 20 (3): 229-239. doi: https://doi.org/10.1053/j.ackd.2013.01.014
  20. Magee LA, Sharma S, Nathan HL, Adetoro OO, Bellad MB, Goudar S, Macuacua SE, Mallapur A, Qureshi R, Sevene E (2019) The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: a prospective population-level analysis. PLoS medicine 16 (4): e1002783. doi: https://doi.org/10.1371/journal.pmed.1002783
  21. Thakur A, Dangal G (2019) Fetomaternal outcome in women with pregnancy induced hypertension versus normotensive pregnancy. Journal of Nepal Health Research Council 17 (4): 495-500. doi: https://doi.org/10.33314/jnhrc.v17i4.2103
  22. Aabidha PM, Cherian AG, Paul E, Helan J (2015) Maternal and fetal outcome in pre-eclampsia in a secondary care hospital in South India. Journal of family medicine and primary care 4 (2): 257. doi: https://doi.org/10.4103%2F2249-4863.154669
  23. Sengodan SS, Sreeprathi N (2020) Prevalence of hypertensive disorders of pregnancy and its maternal outcome in a tertiary care hospital, Salem, Tamil Nadu, India. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 9 (1): 236-240. doi: https://doi.org/10.18203/2320-1770.ijrcog20196026
  24. Katore FH, Gurara AM, Beyen TK (2021) Determinants of Preeclampsia Among Pregnant Women in Chiro Referral Hospital, Oromia Regional State, Ethiopia: Unmatched Case–Control Study. Integrated Blood Pressure Control 14: 163-172. doi: https://doi.org/10.2147%2FIBPC.S336651
  25. Edirimanne VE, Woo CW, Siow YL, Pierce GN, Xie JY, O K (2007) Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunction in rats. Canadian journal of physiology and pharmacology 85 (12): 1236-1247. doi: https://doi.org/10.1136/bmj.38380.674340.E0
  26. Schoenaker DA, Soedamah-Muthu SS, Mishra GD (2014) The association between dietary factors and gestational hypertension and pre-eclampsia: a systematic review and meta-analysis of observational studies. BMC medicine 12 (1): 1-18. doi: https://doi.org/10.1186%2Fs12916-014-0157-7
  27. Shamsi U, Hatcher J, Shamsi A, Zuberi N, Qadri Z, Saleem S (2010) A multicentre matched case control study of risk factors for preeclampsia in healthy women in Pakistan. BMC women's health 10: 1-7. doi: https://doi.org/10.1186/1472-6874-10-14
  28. Li D-K, Wi S (2000) Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. American journal of epidemiology 151 (1): 57-62. doi: https://doi.org/10.1093/OXFORDJOURNALS.AJE.A010122
  29. Trupin LS, Simon LP, Eskenazi B (1996) Change in paternity: a risk factor for preeclampsia in multiparas. Epidemiology 7 (3): 240-244. doi: https://doi.org/10.1097/00001648-199605000-00004
  30. Brown CM, Garovic VD (2014) Drug treatment of hypertension in pregnancy. Drugs 74: 283-296. doi: https://doi.org/10.1007/s40265-014-0187-7